Sunil S. Solomon|Shruti H. Mehta|Aylur K. Srikrishnan|Suniti Solomon|Allison M. McFall|Oliver Laeyendecker|David D. Celentano|Hussain Syed Iqbal|Sam Anand|Canjeevaram K. Vasudevan|S. Saravanan|Gregory M. Lucas|M. Suresh Kumar|Mark Sulkowski|Thomas C. Quinn
Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study
Johns Hopkins University|YR Gaitonde Centre for AIDS Research and Education|Johns Hopkins Medicine|Johns Hopkins University|YR Gaitonde Centre for AIDS Research and Education|YR Gaitonde Centre for AIDS Research and Education|Johns Hopkins University|National Institute of Allergy and Infectious Diseases|National Institutes of Health|Johns Hopkins University|Johns Hopkins Medicine|Johns Hopkins University|YR Gaitonde Centre for AIDS Research and Education|YR Gaitonde Centre for AIDS Research and Education|YR Gaitonde Centre for AIDS Research and Education|YR Gaitonde Centre for AIDS Research and Education|Johns Hopkins University|Johns Hopkins Medicine|YR Gaitonde Centre for AIDS Research and Education|Johns Hopkins University|Johns Hopkins Medicine|National Institute of Allergy and Infectious Diseases|National Institutes of Health|Johns Hopkins University|Johns Hopkins Medicine
90 individuals infected hepatitis c virus hcv worldwide reside resourcelimited settings aimed characterise prevalence hcv hivhcv coinfection hcv care continuum people inject drugs india14 481 people including 31 seedsindividuals selected starting point sampling well connected drug using community inject drugs sampled 15 cities throughout india using respondentdriven sampling jan 2 2013 dec 19 2013 data seeds excluded analyses hcv prevalence estimated presence antihcv antibodies incorporating respondentdriven sampling weights hcv care continuum outcomes selfreported except viral clearance treatmentexperienced participantsthe median age participants 30 years iqr 2436 13 608 924 14 449 men data missing variables weighted hcv prevalence 5777 372 14 447 hivhcv coinfection prevalence 2085 132 14 435 correlates hcv infection included high lifetime injection frequency hiv positivity high prevalence people hiv rna 1000 copies per ml community 5777 people inject drugs hcv antibody positive 440 55 aware status 225 30 seen doctor hcv 79 14 taken hcv treatment 18 04 undetectable hcv rna 12 128 participants previously tested hcv 6138 505 get tested heard hcv 5777 people hcv antibody positive 2086 344 reported harmful hazardous alcohol use 1082 504 dependent 3821 653 reported needle sharing awareness hcv positive status significantly associated higher education hiv testing history awareness hiv positive status higher community antiretroviral therapy coveragethe high burden hcv hivhcv coinfection coupled lowaccess hcv services emphasises urgent need include resourcelimited settings global hcv agenda although new treatments become available worldwide near future programmes improve awareness reduce disease progression transmission need scaled without delay failure could result patterns rising mortality undermining advances survival attributed widespread hiv treatmentus national institutes health